2seventy bio Inc [TSVT] stock is trading at $4.95, saw in change for the day. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TSVT shares have gain 86.09% over the last week, with a monthly amount glided 107.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
2seventy bio Inc [NASDAQ: TSVT] stock has seen the most recent analyst activity on June 06, 2024, when Goldman downgraded its rating to a Sell and also revised its price target to $2 from $5. Previously, Leerink Partners upgraded its rating to Outperform on January 31, 2024, and elevated its price target to $18. On January 31, 2024, downgrade downgraded it’s rating to Market Perform. Leerink Partners downgraded its rating to a Market Perform but stick to its price target of $6 on October 30, 2023. Citigroup initiated its recommendation with a Buy and recommended $13 as its price target on October 12, 2023. Goldman downgraded its rating to Neutral for this stock on September 13, 2023, but kept the price target unchanged to $5. In a note dated September 12, 2023, Guggenheim downgraded an Neutral rating on this stock.
2seventy bio Inc [TSVT] stock has fluctuated between $2.29 and $5.99 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. 2seventy bio Inc [NASDAQ: TSVT] shares were valued at $4.95 at the most recent close of the market. An investor can expect a potential drop of -59.6% based on the average TSVT price forecast.
Analyzing the TSVT fundamentals
2seventy bio Inc [NASDAQ:TSVT] reported sales of 45.62M for the trailing twelve months, which represents a growth of 12.46%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -3.13%, Pretax Profit Margin comes in at -2.07%, and Net Profit Margin reading is -2.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.41 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.94 points at the first support level, and at 4.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.96, and for the 2nd resistance point, it is at 4.97.
Ratios To Look Out For
For context, 2seventy bio Inc’s Current Ratio is 4.95. As well, the Quick Ratio is 4.95, while the Cash Ratio is 1.36. Considering the valuation of this stock, the price to sales ratio is 5.60, the price to book ratio is 1.12.
Transactions by insiders
Recent insider trading involved Kynam Global Healthcare Master, 10% Owner, that happened on Mar 11 ’25 when 11.1 million shares were sold. 10% Owner, Kynam Global Healthcare Master completed a deal on Mar 11 ’25 to sell 5.14 million shares. Meanwhile, Snow Jessica sold 5114.0 shares on Jan 06 ’25.
